DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Status
- COMPLETED
- Phase
- PHASE2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Status
- UNKNOWN
- Phase
- PHASE2
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
- Status
- COMPLETED
- Phase
- PHASE3
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2